合作区将重点推动"四新"产业和澳资产业发展 横琴将加强重点产业规模和发展能级来促进澳门经济适度多元发展。 《规划》明确，到2029年澳门回归祖国30周年时，合作区与澳门经济高度协同、规则深度衔接的制度体系全面确立，市场准入制度高效衔接。各类要素跨境 流动高效便捷，电子围网系统和跨境金融管理体系建立健全，货物"一线放开、二线管住"的体系高效运转，人员出入境高度便利。同时，特色产业发展形成 规模，"四新"产业增加值占地区生产总值比重从2024年的59.4%提升至65%。澳资产业增加值从2024年的30.04亿元增加至90亿元。 6月30日，《横琴粤澳深度合作区产业发展规划（2025—2029年）》（下称《规划》）印发，明确了横琴粤澳深度合作区（下称"合作区"）接下来几年时间 里，在重点产业培育、营商环境建设和琴澳产业一体化等方面的发展思路。 "横琴合作区产业发展的前景，跟同澳门展开深度合作有密切关系。"中山大学岭南学院经济学教授林江告诉第一财经，横琴最重要的机遇是通过粤澳深度合 作，来为澳门中小企业提供一个创新升级的机会。 Film B Har Car . I H T = K HU.U. 上海 Tom The F ...

Core Viewpoint - The successful IPO of Wuhan Heyuan Biotechnology Co., Ltd. marks a significant milestone as the first company to pass the listing review under the fifth set of standards for the Sci-Tech Innovation Board since its restart, reflecting the regulatory support for innovative biotech firms [1][3]. Group 1: Company Overview - Wuhan Heyuan Biotechnology, established in 2006, focuses on the "recombinant human albumin" sector, which is considered a blue ocean market [3]. - The company's core product, HY1001 (recombinant human albumin injection), has completed Phase III clinical trials and is expected to receive approval for market launch soon, potentially becoming the first recombinant human albumin drug in China [3]. - Currently, Heyuan's revenue primarily comes from pharmaceutical excipients and research reagents, with its core innovative drug still in development and not yet generating income, leading to a loss [3]. Group 2: Industry Context - As of now, 20 companies have utilized the fifth set of standards for listing on the Sci-Tech Innovation Board, with 19 being innovative drug development firms and 1 in high-end medical device development [4]. - In 2024, these 20 companies collectively generated over 14 billion yuan in revenue, representing a growth of over 40% compared to 2023, with 16 companies achieving revenues exceeding 1 billion yuan, and 4 surpassing 10 billion yuan [4]. - The first quarter of 2025 saw these companies continue their growth trend, achieving a total revenue of 3.78 billion yuan, a year-on-year increase of 29.27% [4]. - From 2018 to the first quarter of 2025, companies under the fifth set of standards have launched 17 new Class 1 drugs, accounting for approximately 12% of the total number of domestic innovative drugs approved during the same period [4]. Group 3: Regulatory Environment - The successful IPO of Heyuan is seen as a practical example of the China Securities Regulatory Commission's policy to enhance the inclusivity and adaptability of the Sci-Tech Innovation Board, particularly in supporting high-quality technology enterprises [3][4]. - The pace of IPO applications on the Sci-Tech Innovation Board has accelerated, with over 30 applications received in the first half of the year, of which more than 70% are from Sci-Tech Innovation Board companies [5].

整理 | GLP1减重宝典内容团队 6月30日，泰德医药在香港交易所正式挂牌上市，由摩根士丹利与中信证券担任联席保荐人。公司H股发行价定为每股30.60港元，总市值达 43.49亿港元。开盘初期，股价一度上涨近4%，触及31.8港元。 | 30.800+ | 国际 国际 | 32.850 今 开 | 30.300 | | --- | --- | --- | --- | | +0.200 +0.65% | 最低 | 28.100 昨 收 | 30.600 | | | 成交额 2.72亿 市盈率TTM 68.29 总市值 - 43.67亿 | | | | 成交量 | 859.38万股 市盈率(静) 201 | 68.29 总股本 | 1.42亿 | | 换手率 | 11.68% 市净率 1 12.69 流通值 1 | | 22.67亿 | | 52周最高 | 32.850 委 比 -- -- | 51.18% 流通股 | 7360万 | | 52周最低 | 28.100 量 比 | -- 振 幅 幅 -- | 15.52% | | 历史最高 | 32.850 股息TTM | -- 股息率TM | | | 历史最低 ...

Group 1 - Yunzhi Voice Technology Co., Ltd. listed on the Hong Kong Stock Exchange on June 30, becoming the "first AGI stock" in Hong Kong [1] - Yunzhi was founded in 2012 and has developed AI solutions based on deep learning models, including its core algorithm model UniCore [1] - The company has received investments from notable institutions such as Sequoia Capital, JD.com, and Qualcomm, with a significant investment from Sichuan Innovation and Entrepreneurship Equity Investment Fund in 2017 [1] Group 2 - Moore Threads submitted its prospectus for listing on the Sci-Tech Innovation Board, focusing on full-function GPU chip development [2] - The company supports various workloads including AI computing acceleration and 3D graphics rendering [2] - Chengdu Ciyuan Guoyi Electronic Information Equity Investment Fund invested in Moore Threads in 2023 [2] Group 3 - Wuhan Heyuan Biotechnology Co., Ltd. is preparing for an IPO on the Sci-Tech Innovation Board, with its core product HY1001 nearing market approval [2] - HY1001 is a new drug that has completed Phase III clinical trials and is under priority review by the National Medical Products Administration [2] Group 4 - Yaoke Ankang Technology Co., Ltd. successfully listed on the Hong Kong Stock Exchange on June 23, with significant investment from the National Investment (Guangdong) Technology Achievement Transformation Venture Capital Fund [5] - The company focuses on innovative drug development for cancer, inflammation, and cardiovascular diseases, with multiple candidates in clinical stages [5] Group 5 - Sichuan Southwest Jiaotong Railway Development Co., Ltd. listed on the Beijing Stock Exchange on June 10, specializing in rail transportation infrastructure safety [6] - The company is recognized as a national-level "little giant" enterprise and is the first IPO project of the Sichuan Science and Technology Investment's Academician Fund [6] - Multiple local funds, including Chengdu Lixin Jingrong Fund, participated in the investment of Jiaotong Railway Development [6]

Core Viewpoint - Chengdu Xian Dao Pharmaceutical Development Co., Ltd. has terminated its acquisition of Nanjing Haina Pharmaceutical Technology Co., Ltd. due to failure to reach consensus on key transaction terms, but it does not expect any adverse impact on its business operations or financial status [1][3]. Company Overview - Chengdu Xian Dao is a rapidly developing biotechnology company focused on new drug research and development, listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board since April 2020 [7]. - The company has experienced revenue fluctuations post-IPO, but has shown stable growth in recent years, with projected revenues of 4.27 billion yuan for 2024, reflecting a year-on-year growth of 14.99% [7]. Financial Performance - Chengdu Xian Dao's revenue from 2020 to 2024 is reported as follows: 2.44 billion yuan, 3.11 billion yuan, 3.30 billion yuan, 3.71 billion yuan, and 4.27 billion yuan, with year-on-year changes of -7.8%, 27.69%, 5.98%, 12.64%, and 14.99% respectively [7]. - The net profit attributable to shareholders for the same period is 640.2 million yuan, 633.8 million yuan, 252.7 million yuan, 407.2 million yuan, and 513.6 million yuan, with year-on-year changes of -46.77%, -1.00%, -60.14%, 61.16%, and 26.13% respectively [7]. Shareholder Activity - Since 2024, Chengdu Xian Dao has faced frequent shareholder reductions, with a total cash-out of 294 million yuan [8]. - Specific instances of share reductions include a 1.20% stake sold for 78.98 million yuan and a 0.50% stake sold for 31.75 million yuan [9]. Nanjing Haina Pharmaceutical Overview - Nanjing Haina is focused on improved innovative drugs and high-end generic drugs, operating under a "CXO + MAH" business model [3]. - The company submitted an IPO application in June 2023, aiming to raise 850 million yuan, but its application was terminated in June 2024 due to the withdrawal of its sponsor [3][4]. Financial Performance of Nanjing Haina - Nanjing Haina's revenue from 2020 to 2023 is reported as follows: 56.82 million yuan, 168 million yuan, 271 million yuan, and 226 million yuan, with a compound annual growth rate of 118.37% from 2020 to 2022 [4]. - The net profit attributable to shareholders for the same period is -28.71 million yuan, 11.57 million yuan, 68.02 million yuan, and 73.18 million yuan [4]. - As of June 30, 2023, Nanjing Haina's undistributed profits stood at -142 million yuan [4]. Sales and Accounts Receivable - Nanjing Haina's sales expenses have increased significantly, with figures of 3.94 million yuan, 14.46 million yuan, 21.88 million yuan, and 15.41 million yuan over the same period, resulting in a sales expense ratio that is nearly double the industry average [5]. - Accounts receivable have also risen sharply, with balances of 3.01 million yuan, 20.33 million yuan, 41.85 million yuan, and 83.49 million yuan, reflecting a compound growth rate of 269.1% from 2020 to 2022 [5].

Group 1 - The core viewpoint of the article is the issuance of measures by the National Healthcare Security Administration and the National Health Commission to support the high-quality development of innovative drugs, particularly encouraging commercial health insurance to expand investment in innovative drugs [1] Group 2 - The measures encourage commercial health insurance companies to provide stable and long-term investment for innovative drug research and development through various means, such as innovative drug investment funds [1] - The initiative aims to cultivate patient capital that supports innovative drugs [1]

格蓝若机器人团队正在进行机器人研发攻关。 长江日报记者徐丹 摄 【开栏的话】 今天，我们迎来中国共产党成立104周年。本报今起推出"英雄城市·先锋有我"专栏，深 入挖掘一批基层党组织和党员立足岗位、干事创业的生动实践和典型事迹，展示全市广大党 员提能力、转作风、拼业绩、比贡献的新气象，为支点建设、转型发展凝聚先锋力量。 □ 长江日报记者徐丹 通讯员顾澳丽 6月30日，武汉格蓝若智能机器人有限公司（以下简称"格蓝若"）实验室内，工程师们 正紧张测试"大壮""小壮"和机器狗。随着项目管理主管陈燕一声令下，机器人稳健迈步，数 据曲线完美吻合，现场响起热烈掌声。 科技创新发展需要党建工作的有力引领。格蓝若党支部秉持"先锋领航"实践和拼搏精 神，短短7个月，让人形机器人实现从0到1的突破，生动践行了科技自立自强的使命担当。 ■ 突击队立下军令状 身高1.8米、体重95公斤，采用自主研发的运动控制算法，可负重40～60公斤并实现直 膝行走……这是格蓝若常务副总经理熊少华带领的格蓝若"党员先锋队"与华中科技大学陈学 东院士团队联合研发的"劳动者"系列机器人，乳名"大壮"。 现在"大壮"已实现独立行走、负重行走、上下楼梯、爬 ...

Investment Overview - The company intends to acquire up to 20.1667% equity in Ningbo Jujia New Materials Technology Co., Ltd. for a total price not exceeding 121 million RMB [1][5] - The acquisition will be made through cash payment and does not constitute a related party transaction or a major asset restructuring as per regulations [1][2] Target Company Information - Ningbo Jujia New Materials Technology Co., Ltd. was established on November 27, 2017, with a registered capital of approximately 14.2 million RMB [2][3] - The company specializes in technology services, research and development of bio-based materials, and manufacturing of synthetic materials [2][3] Financial Data - The target company's total assets as of the latest reporting period amount to approximately 389.4 million RMB, with total liabilities of about 280.8 million RMB [3] - The company reported a net loss of approximately 6.1 million RMB in the latest financial period [3] Transaction Details - The investment agreement is currently a non-binding intention, and further due diligence will be conducted before a formal agreement is signed [4][11] - The transaction is subject to various conditions, including the completion of due diligence and internal approvals from both parties [6][8] Strategic Importance - The acquisition is expected to enhance the company's capabilities in the new materials sector, particularly in high-performance LCP fibers and resins, which have applications in aerospace, industrial transport, and high-end cables [10] - Successful completion of the investment will support the company's expansion into emerging fields such as automotive electronics and humanoid robotics [10]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 本公告乃由本公司自願作出。 董事會欣然宣佈，於二零二五年六月三十日（聯交所交易時段後），本公司（作 為買方）已與賣方及Conflux訂立諒解備忘錄，內容有關收購目標公司全部股 權的潛在收購事項，前提為目標公司按照與本公司的協議完成收購Conflux 資產。 潛在收購事項須待本公司與賣方訂立正式協議後方可作實。因此，潛在收 購事項未必會進行。本公司將根據上市規則適時刊發公告。股東及本公司 潛在投資者於買賣本公司股份時務請審慎行事。 – 1 – INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED 領航醫藥及生物科技有限公 司 （於開曼群島註冊成立並於百慕達存續之有限公 司） （股份代 號：399） 自願公告 有關潛在收購事項的 諒解備忘錄 緒言 董事會欣然宣佈，於二零二五年六月三十日（聯交所交易時段後），本公司（作 為買方）已與賣方及Conflux訂立諒解備忘錄，內容有關潛在 ...

Core Viewpoint - 泰德医药 (Zhejiang Taide Pharmaceutical Co., Ltd.) has successfully listed on the Hong Kong Stock Exchange, with an initial trading price of 30.3 HKD and a closing price of 30.8 HKD, reflecting a slight increase of 0.65% on the first day of trading [1]. Summary by Relevant Sections IPO Details - The final offer price for the shares was set at 30.6 HKD, raising a total of 514.08 million HKD. After deducting estimated listing expenses of 85.31 million HKD, the net proceeds amounted to 428.77 million HKD [3][4]. Share Distribution - A total of 16,800,000 H-shares were issued, with an equal split of 8,400,000 shares allocated for public offering in Hong Kong and international offering [1]. Key Investors - The cornerstone investors for the IPO include Shiyao and Welight Capital [4]. Business Focus - The company primarily provides Contract Research Organization (CRO) services, focusing on peptide NCE discovery synthesis, and Contract Development and Manufacturing Organization (CDMO) services, which include peptide CMC development and commercial production. The services are mainly centered on providing Active Pharmaceutical Ingredients (API) rather than finished drugs [4]. Use of Proceeds - The funds raised will be utilized for expanding service capabilities and production capacity in the U.S. and China, increasing production capacity in China, establishing sales and after-sales service networks in more regions, and general corporate purposes [4]. Financial Performance - Projected revenues for 2022, 2023, and 2024 are 351 million RMB, 337 million RMB, and 442 million RMB, respectively. The net profits for the same years are expected to be 53.98 million RMB, 48.91 million RMB, and 59.17 million RMB [5][6].